Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Good 10-year performance for St Jude's heart valve:

This article was originally published in Clinica

Executive Summary

St Jude Medical has announced positive results for a 10-year follow-up study of its stentless tissue heart valve. The Toronto SPV valve, which was approved by the US FDA in 1997, was designed to improve the haemodynamic performance and extend durability over conventional stented tissue valves. The study of 447 patients found that, regarding durability, 88% of patients did not need a new valve implant. Also, 95% of patients were free of valve related deaths by the end of the study. According to the St Paul, Minnesota firm, clinical performance was maintained and patient satisfaction was high.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT064046

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel